Adding Ipilimumab to Brentuximab Vedotin Plus Nivolumab Did Not Improve Complete Response, but May Prolong Disease Control Without Transplant in Relapsed Hodgkin Lymphoma

Highlights

In the randomized phase 2 Intergroup E4412 trial, adding ipilimumab to brentuximab vedotin and nivolumab did not significantly improve the primary end point of complete response rate in relapsed/refractory classic Hodgkin lymphoma.

Complete response rates were high in both arms: 64.7% with brentuximab vedotin plus nivolumab and 70.3% with brentuximab vedotin plus ipilimumab and nivolumab, with no statistically significant difference.